1361249-09-3

Upstream product

• 1361295-43-3 C₁₉H₁₉N₃ 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1361249-52-6 (S)-tert-butyl 2-(5-([1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylare 
• 1004904-88-4 (S)-2-(2-([1,1'-biphenyl]-4-yl)-2-oxoethyl)1-tert-butyl pyrrolidine-1,2-dicarboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Relevant academic research and scientific papers

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors

Based on the symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed. The synthesis of 36 new non-dimeric NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. Among them compound 5a showed picomolar range activity along with an excellent selectivity index (SI > 90,000).

POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and othe